🚀 VC round data is live in beta, check it out!
Alzinova Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alzinova and similar public comparables like Liminatus Pharma, Pure Biologics, Opsy Holding, CalciMedica and more.
Alzinova Overview
About Alzinova
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer’s.
Founded
2011
HQ
Employees
5
Website
Sectors
Financials (LTM)
EV
$8M
Alzinova Financials
Alzinova reported last 12-month revenue of — and negative EBITDA of ($4M).
In the same LTM period, Alzinova generated — in gross profit, ($4M) in EBITDA losses, and had net loss of ($3M).
Revenue (LTM)
Alzinova P&L
In the most recent fiscal year, Alzinova reported revenue of — and EBITDA of ($3M).
Alzinova expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | $3M | XXX | XXX | XXX |
| EBITDA | ($4M) | XXX | ($3M) | XXX | XXX | XXX |
| Net Profit | ($3M) | XXX | ($2M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alzinova Stock Performance
Alzinova has current market cap of $10M, and enterprise value of $8M.
Market Cap Evolution
Alzinova's stock price is $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8M | $10M | 0.3% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlzinova Valuation Multiples
Alzinova trades at (2.3x) EV/EBITDA.
EV / Revenue (LTM)
Alzinova Financial Valuation Multiples
As of April 19, 2026, Alzinova has market cap of $10M and EV of $8M.
Equity research analysts estimate Alzinova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alzinova has a P/E ratio of (3.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV/EBITDA | (2.3x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.8x | XXX | XXX | XXX |
| P/E | (3.4x) | XXX | (4.4x) | XXX | XXX | XXX |
| EV/FCF | (1.5x) | XXX | (2.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alzinova Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alzinova Margins & Growth Rates
Alzinova's revenue in the last fiscal year declined by (100%).
Alzinova's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Alzinova Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | 95% | XXX | 102% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alzinova Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alzinova | XXX | XXX | XXX | XXX | XXX | XXX |
| Liminatus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pure Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Opsy Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Chosa Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alzinova M&A Activity
Alzinova acquired XXX companies to date.
Last acquisition by Alzinova was on XXXXXXXX, XXXXX. Alzinova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alzinova
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlzinova Investment Activity
Alzinova invested in XXX companies to date.
Alzinova made its latest investment on XXXXXXXX, XXXXX. Alzinova invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alzinova
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alzinova
| When was Alzinova founded? | Alzinova was founded in 2011. |
| Where is Alzinova headquartered? | Alzinova is headquartered in Sweden. |
| How many employees does Alzinova have? | As of today, Alzinova has over 5 employees. |
| Is Alzinova publicly listed? | Yes, Alzinova is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Alzinova? | Alzinova trades under ALZ ticker. |
| When did Alzinova go public? | Alzinova went public in 2015. |
| Who are competitors of Alzinova? | Alzinova main competitors are Liminatus Pharma, Pure Biologics, Opsy Holding, CalciMedica. |
| What is the current market cap of Alzinova? | Alzinova's current market cap is $10M. |
| Is Alzinova profitable? | No, Alzinova is not profitable. |
| What is the current EBITDA of Alzinova? | Alzinova has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Alzinova? | Current EBITDA multiple of Alzinova is (2.3x). |
| What is the current FCF of Alzinova? | Alzinova's last 12 months FCF is ($5M). |
| What is the current EV/FCF multiple of Alzinova? | Current FCF multiple of Alzinova is (1.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.